A major defect contributing to impaired insulin action in human obesity is reduced glucose transport activity in skeletal muscle. This study was designed to determine whether the improvement in whole body glucose disposal associated with weight reduction is related to a change in skeletal muscle glucose transport activity and levels of the glucose transporter protein GLUT4. Seven morbidly obese (body mass index = 45.8 +/-2.5, mean +/-SE) patients, including four with non-insulin-dependent diabetes mellitus (NIDDM), underwent gastric bypass surgery for treatment of their obesity. In vivo glucose disposal during a euglycemic clamp at an insulin infusion rate of 40 mU/m2 per min was reduced to 27% of nonobese controls (P less than 0.01) and improved to 78% of normal after weight loss of 43.1 +/-3.1 kg (P less than 0.01). Maximal insulin-stimulated glucose transport activity in incubated muscle fibers was reduced by approximately 50% in obese patients at the time of gastric bypass surgery but increased twofold (P less than 0.01) to 88% of normal in five separate patients after similar weight reduction. Muscle biopsies obtained from vastus lateralis before and after weight loss revealed no significant change in levels of GLUT4 glucose transporter protein. Abstract A major defect contributing to impaired insulin action in human obesity is reduced glucose transport activity in skeletal muscle.
Introduction
Peripheral insulin resistance is a primary disorder in both obesity and non-insulin-dependent diabetes mellitus (NIDDM)' (1) (2) (3) . This appears to be due at least in part to a defect in skeletal muscle, the major site of whole body insulin-dependent glucose disposal (2) (3) (4) . Using a novel in vitro human muscle preparation, we recently demonstrated that insulin-stimulated glucose transport was severely decreased by 50% in muscle of morbidly obese patients with or without NIDDM (5) . Although the primary defect(s) responsible for the insulin resistance is still unknown, one possible candidate for this defect is the glucose transporter, since glucose transport is the rate-limiting step for glucose utilization in muscle (6, 7) .
The glucose transport response in insulin-sensitive tissues such as muscle and fat is predominantly mediated by the unique glucose transporter isoform GLUT4 (8) . Garvey et al. (9) recently demonstrated that the cellular insulin resistance in adipocytes from obese and obese-NIDDM patients is accompanied by a 40-80% depletion of GLUT4 glucose transporter protein. However, the mechanism underlying the severe defect in glucose transport activity in skeletal muscle is much less clear. Pederson et al. (10) and Handberg et al. ( 11) reported no significant change in levels of muscle GLUT4 protein in vastus lateralis of obese NIDDM patients compared with lean controls. On the other hand, our group recently reported that GLUT4 protein is decreased by -20% in both rectus abdominis and vastus lateralis muscles in morbidly obese patients, with or without NIDDM (12) . This discrepancy may be due in part to the heterogeneity of the obesity syndrome, as well as a large biological variability in muscle GLUT4 protein found in normal subjects (10) (11) (12) .
Given that decreased glucose transport is a major mechanism underlying insulin resistance, we sought to determine whether muscle GLUT4 transporter protein contributes to the insulin resistance of skeletal muscle by examining levels ofglucose transporter protein GLUT4 in the same patients before and after a period ofweight loss, which has been shown to be an effective means of improving peripheral glucose disposal (13-16). In addition to muscle glucose transporter GLUT4, we examined whole body glucose disposal and glucose transport activity in muscle from patients after weight loss to permit comparisons of changes in muscle glucose transporter protein with changes in insulin action in vivo and muscle transport activity Subjects. Subject characteristics are listed in Table I . Seven morbidly obese patients (body mass index [BMI] > 40 kg/m2) scheduled for gastric bypass surgery were studied. Of these patients, four were classified as having NIDDM and three were classified as nondiabetic, according the criteria established by the National Diabetes Data Group (17). None of the subjects had any disease other than diabetes and/or obesity and were weight stable for 2 2 mo before entry into the study. Of the four diabetics, two were on insulin and two were being treated with oral agents. The experimental protocol was explained to each subject, and informed consent was obtained. The project was approved by the East Carolina University Policy and Review Committee on Human Research.
Euglycemic clamp and muscle biopsies. In vivo glucose disposal was assessed and muscle biopsies obtained I mo before gastric bypass surgery and again after a stable body weight was achieved, -12 mo after gastric bypass surgery. After surgery all patients were followed at 6-8-wk intervals for weighing and dietary counseling. A plateau in weight was declared when three consecutive weights varied by > 1 kg. 2 wk before the study diabetic patients were withdrawn from therapy with consent and were followed on an outpatient basis. Subjects received a weight-maintaining diet containing 50% of total calories as carbohydrates, 30% as fat, and 20% as protein for 3 d before each clamp. Subjects were admitted to the Outpatient Clinical Research Unit of the East Carolina University School of Medicine at 8:00 a.m. after an overnight fast. A 50-100-mg muscle sample was obtained from the vastus lateralis muscle using the percutaneous muscle biopsy technique as described previously (12) . The muscle tissue was rinsed and dissected free of connective tissue, quick frozen on dry ice, and stored at -70°C until analysis for GLUT4 protein. The subjects then underwent a 2-h hyperinsulinemic euglycemic clamp (without radioactivity) to determine in vivo glucose disposal as described in detail previously (18, 19) . A continuous insulin infusion rate of 40 mU/m2 per min was used and plasma glucose was maintained between 80 and 90 mg/dl throughout the test by a variable infusion of20% dextrose. The glucose disposal rate (M) = mg/m2 per min was calculated using the exogenous glucose infusion rate during the final 30 min of euglycemia.
Analytical methods. Plasma glucose was analyzed by the glucose oxidase method (glucose analyzer II; Beckman Instruments Inc., Fullerton, CA). Insulin was analyzed by double antibody radioimmunoassay using a kit supplied by Cambridge Diagnostics (Billerica, MA) according to the method of Desbuquois and Aurbach (20) . Glycosylated hemoglobin was determined in heparinized blood using the fast hemoglobin test system kit (Isolab, Inc., Akron, OH).
2-deoxy-D-glucose transport in human musclefiber strips. Glucose transport activity was determined in rectus abdominis muscle obtained from seven morbidly obese patients during gastric bypass surgery for the treatment of their obesity (21) and from five former gastric bypass patients undergoing elective abdominal surgery, as described previously (5). After an overnight fast, general anesthesia was induced with a short-acting barbiturate and maintained by fentanyl and N20-02 mixture. Only saline was given intravenously before the biopsy. After exposing the rectus abdominis, a 3 X 2 X 2 cm biopsy was clamped, excised, and quickly transported to the laboratory in oxygenated Krebs-Henseleit buffer. Muscle fiber strips weighing 40-80 mg were teased from the muscle and a smaller clamp (2 cm) was placed on the muscle fiber strip before it was cut free. Muscles were incubated in 4.0 ml of medium consisting of Krebs-Henseleit buffer, 1% bovine serum albumin, 1.0 mM pyruvate, at 0, 1 X 10', and 1 x 10' M insulin.
Transport was measured in the presence of 5 mM 2-deoxy-D-glucose for 60 min as described previously (5) .
Analysis ofglucose transporter protein.
To minimize any contribution of interassay variability, muscle samples from each subject's preand post-weight reduction biopsies were prepared and analyzed for GLUT4 protein in the same assay. The procedufes for quantifying GLUT4 are described here and elsewhere in detail (12, 19) . Muscle biopsies were homogenized (Polytron; Brinkmann Instruments, Inc., Westbury, NY) in 2 ml ofcold (4°C) buffer (pH 7.4) containing 25 mM Hepes, 25 mM benzamidine, 4 mM EDTA, 0.5 mM PMSF, and 1 ,uM each of leupeptin, pepstatin, and aprotinin. To isolate cellular membranes, samples were centrifuged at 150,000 g for 1 h at 4°C. The resulting pellet was rinsed and resuspended (Polytron) in cold buffer. Triton was added to each resuspension to give a final concentration of 1%. The samples were allowed to sit on ice for 1.5 h to solubilize the membrane-bound protein. After a final spin (150,000 g, 1 h, 4°C), the supernatant was removed and used for Western analysis. Duplicate samples containing 50 gg protein (BCA procedure; Pierce Chemical Co., Rockford, IL) were mixed overnight at 4°C with Laemmli sample buffer (22) containing 2.5% dithiothreitol and 1% SDS. Proteins were separated by SDS-PAGE under reducing conditions on an 8% resolving gel and transferred to Immobilon membrane (Millipore Corp., Bedford, MA) by electrotransfer (500 mA, 2 h). The membrane was blocked for 2 h in 5% Carnation low-fat instant milk in Tris-buffered saline (TBS-blotto), followed by incubation for 16 h at 4°C in polyclonal antibody (1 gg/ml in TBS-blotto) specific for the GLUT4 transporter isoform. The membrane was washed in TBS/TBS-Tween and incubated 1 h at 25°C in 50 ml TBS-blotto containing donkey antirabbit antibody conjugated to horseradish peroxidase (1:4,000). GLUT4 was visualized using an enhanced chemiluminescence detection system (Amersham, Corp., Arlington Heights, IL). Membranes were washed in TBS/TBS-Tween and incubated for 1 min in detection reagent (luminol + H202), followed by exposure to Hyperfilm (Amersham Corp.) for 10-30 s. The resulting films were analyzed by scanning densitometry.
Statistical analysis. All data are given as mean ± SEM. Paired t test was used to determine differences between the same patients before and after weight loss. Glucose transport in five separate morbidly obese patients after weight loss was compared with the obese patients and previously published data on nonobese controls (5) using one-way analysis of variance. Newman-Keuls post-hoc testing was used to determine significant differences between groups.
Results
The subject characteristics are presented in Effect ofweight loss on 2-deoxyglucose transport. For ethical reasons, we were unable to obtain rectus muscle from the same patients after weight loss. However, we were able to study glucose transport activity in rectus abdominis muscle from a similar group of patients undergoing revision (n = 2), hernia repair (n = 2), or abdominoplasty (n = 1) 15-24 mo after gastric bypass surgery. These patients had stabilized in body weight after a similar weight loss of 27-49 kg (BMI = 31.3±2.8 kg/M2). As shown in Fig. 2 , maximal insulin-stimulated glucose transport activity was increased 1.9±0.3-fold over basal (range, 1.3-2.9) in patients after weight loss (P < 0.01). Insulinstimulated glucose transport activity in morbidly obese patients at the time of gastric bypass was 50% of nonobese nondiabetic patients, published previously (5), and these data are now presented together with our previous work. The values for glucose transport in patients after weight loss reveal an approximately twofold increase in maximal glucose transport activity from 25 .3±3.3 to 48.2±7.3 nmol/g dry wt per min (P < 0.01). Thus, weight loss restored maximal insulin-stimulated skeletal muscle glucose transport activity to 88% of normal, nonobese patients. Lack of tissue prevented us from performing a complete insulin dose-response curve in incubated muscle; however, at a single submaximal concentration of insulin (10-' M) glucose transport activity increased significantly from 25.3±3.3 to 37.3±5.1 nmol/g dry wt per min (P < 0.05). This value corresponds to 83% of nonobese nondiabetic subjects at the same insulin concentration (data not shown).
To determine whether the improvement in insulin-stimulated glucose transport capacity could be accounted for by increased levels of the insulin-sensitive glucose transporter protein GLUT4, muscle biopsies were obtained from vastus lateralis muscle in the gastric bypass patients before and after weight loss. Identical amounts of total membrane protein were size fractionated by SDS-PAGE, transferred to nitrocellulose membrane, and detected using an affinity purified COOH-terminal anti-GLUT4 antibody. Muscle fiber strips were prepared as outlined previously (5) r levels in muscle in the with other investigators using a variety of in vivo and in vitro t loss. In all subjects, techniques, have suggested that decreased glucose transport acin. GLUT4 was quantitivity is a major defect contributing to impaired insulin action es are shown in Fig. 3B .
in human obesity (3, 6, 9, 23) . In morbidly obese subjects pe-I slightly in six of seven ripheral glucose disposal is markedly decreased compared with nonsignificant decrease nonobese controls, and this may be due to the severe decrease se transporter protein in muscle glucose transport activity found here and in our prenbrane protein did not vious study (5 (34, 35) . Although the regulation ofglucose transport activity probably involves factors other than just activation of tyrosine kinase, it is likely that this or some other defect of insulin signaling more distal to the insulin receptor is responsible for decreased glucose transport activity observed in human obesity. Such a defect may impair the function of the GLUT4 transporter either through decreased activation and/or translocation to the plasma membrane.
